



Nevada Medicaid

Submit fax request to: 855-455-3303

Please note: All information below is required to process this request.

Forteo® (teriparatide) Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED.

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand <input type="checkbox"/> Check if request is for initial therapy <input type="checkbox"/> Check if request is for recertification of therapy			Directions for Use:		
Clinical Information (required)					
Select the diagnosis below:					
<input type="checkbox"/> Diagnosis of postmenopausal osteoporosis or osteopenia					
<input type="checkbox"/> Diagnosis of primary or hypogonadal osteoporosis or osteopenia					
<input type="checkbox"/> Diagnosis of glucocorticoid-induced osteoporosis (recipient has a documented history of prednisone or its equivalent at a dose greater than or equal to 5 mg/day for greater than or equal to three months).					
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
Drug-Specific Information (required)					
<input type="checkbox"/> The recipient's Bone Mineral Density (BMD) T-score is -2.5 or lower in the lumbar spine, femoral neck, total hip or radius (one-third radius site).					
<input type="checkbox"/> The recipient has a BMD T-score between -1.0 and -2.5 in the lumbar spine, femoral neck, total hip or radius (one-third radius site).					
<input type="checkbox"/> The recipient has documented history of low-trauma fracture of the hip, spine, proximal humerus, pelvis or distal forearm.					
<input type="checkbox"/> The recipient has documented trial and failure, contraindication, or intolerance to one anti-resorptive treatment (e.g., alendronate, risedronate, zoledronic acid, Prolia® [denosumab]).					
<input type="checkbox"/> The recipient has a FRAX 10-year probability of a major osteoporotic fracture at 20% or more in the U.S., or the country-specific threshold in other countries or regions.					
<input type="checkbox"/> The recipient has a FRAX 10-year probability of a hip fracture at 3% or more in the U.S., or the country-specific threshold in other countries or regions.					
<input type="checkbox"/> Treatment duration of parathyroid hormones has not exceeded a total of 24 months during the recipient's lifetime.					

Attach any additional comments, diagnoses, symptoms, medications tried or failed, or other information the physician feels is important to this review.

Please note: This request may be denied unless all required information is received. For urgent or expedited requests please call 1-800-711-4555. This form may be used for non-urgent requests and faxed to 1-800-527-0531.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**